Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV000507314 | SCV000603794 | pathogenic | not specified | 2017-02-06 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000022139 | SCV000695695 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2016-01-08 | criteria provided, single submitter | clinical testing | Variant summary: Variant of interest affects a conserved nucleotide and results in a replacement of a small size and hydrophobic Glycine (G) with a medium size and acidic Aspartate (D). 4/4 in silico tools predict disease causing outcome for this substitution. The variant is absent from the large and broad cohorts of the ExAC project while it has been observed in galactosemia patients either in compound heterozygosity with a common mutation Q188R or in homozygosity indicating the variant to be deleterious. Additionally, Coelho_MGGM_2014 demonstrated the variant to impair the catalytic activity of GALT further supporting a disease causing impact. Moreover, a clinical diagnostic laboratory classifies variant as pathogenic via Clinvar (without evidence to independently evaluate). Considering all evidence, the variant was classified as Pathogenic. |
Revvity Omics, |
RCV000022139 | SCV004238210 | likely pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2023-07-06 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001276270 | SCV001462319 | pathogenic | Galactosemia | 2020-09-16 | no assertion criteria provided | clinical testing |